西酞普兰对恶性肿瘤患者抑郁症状的随机双盲对照研究

摘要

目的 以随机双盲对照研究明确西酞普兰在肿瘤患者伴随抑郁症的疗效和安全性。方法 188例恶性肿瘤伴随抑郁症患者随机分为两组，分别给以西酞普兰和安慰剂治疗6周。采用汉密尔顿抑郁量表(HAMD-17),汉密尔顿焦虑量表i(HAMA)于治疗前和治疗1、2、4、6周末分别评定疗效。结果 西酞普兰组总有效率62.22％，治疗后HAMD和HA MA评分均较治疗前下降，同安慰剂对照组相比差异有显著性（P＜0.05）。两组不良反应发生率轻微，比较差异无显著性(P＞0.05）。结论 西酞普兰治疗肿瘤患者伴随抑郁症疗效确切，不良反应轻微。%Objectives To evaluate efficacy and safety of citalopram in the treatment of depression of cancer patients. Methods In the 6-week, randomized, double-blind and parallel controlled clinical trial, 188 patients were randomly divided into citalopram group and placebo group. All the patients were assessed with HAMD-17, HAMA before treatment and after 1, 2, 4 and 6 weeks of treatment.Safety measures included adverse reactions observation. Results The total effective rates of the escitalopram group 62.22％. The scores of HAMD 17 and HAMA in citalopram decreased significantly,with statistically difference compared with the baseline and placebo group. Conclutions Citalopram is an effective and safety antidepressant treatment to depression in cancer patients.